[HTML][HTML] Recent advances in antiviral drug development towards dengue virus
B Troost, JM Smit - Current opinion in virology, 2020 - Elsevier
Highlights•Evaluating drug efficacy, specificity and toxicity may help to develop an optimal
treatment regime for in vivo studies.•Measuring time to resolve viremia in vivo may help to …
treatment regime for in vivo studies.•Measuring time to resolve viremia in vivo may help to …
Molecular mechanisms of antiviral agents against dengue virus
Dengue is a major global health threat causing 390 million dengue infections and 25,000
deaths annually. The lack of efficacy of the licensed Dengvaxia vaccine and the absence of …
deaths annually. The lack of efficacy of the licensed Dengvaxia vaccine and the absence of …
The medicinal chemistry of dengue virus
The dengue virus and related flaviviruses are an increasing global health threat. In this
perspective, we comment on and review medicinal chemistry efforts aimed at the prevention …
perspective, we comment on and review medicinal chemistry efforts aimed at the prevention …
Dengue drug discovery: Progress, challenges and outlook
SP Lim - Antiviral research, 2019 - Elsevier
In the context of the only available vaccine (DENGVAXIA) that was marketed in several
countries, but poses higher risks to unexposed individuals, the development of antivirals for …
countries, but poses higher risks to unexposed individuals, the development of antivirals for …
Dengue virus: pathogenesis and potential for small molecule inhibitors
N Chauhan, KK Gaur, TR Asuru… - Bioscience reports, 2024 - portlandpress.com
Dengue, caused by dengue virus (DENV), is now endemic in nearly 100 countries and
infection incidence is reported in another 30 countries. Yearly an estimated 400 million …
infection incidence is reported in another 30 countries. Yearly an estimated 400 million …
Discovering new medicines targeting helicases: challenges and recent progress
WR Shadrick, J Ndjomou, R Kolli… - Journal of …, 2013 - journals.sagepub.com
Helicases are ubiquitous motor proteins that separate and/or rearrange nucleic acid
duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases …
duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases …
Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication
The hepatitis C virus (HCV) nonstructural protein 3 (NS3) is both a protease, which cleaves
viral and host proteins, and a helicase that separates nucleic acid strands, using ATP …
viral and host proteins, and a helicase that separates nucleic acid strands, using ATP …
Benzothiazole and pyrrolone flavivirus inhibitors targeting the viral helicase
The flavivirus nonstructural protein 3 (NS3) is a protease and helicase, and on the basis of
its similarity to its homologue encoded by the hepatitis C virus (HCV), the flavivirus NS3 …
its similarity to its homologue encoded by the hepatitis C virus (HCV), the flavivirus NS3 …
Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the hepatitis C virus life cycle
ABSTRACT Hepatitis C virus (HCV) NS3 is a multifunctional protein composed of a protease
domain and a helicase domain linked by a flexible linker. Protease activity is required to …
domain and a helicase domain linked by a flexible linker. Protease activity is required to …
Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?
SD Martino, GL Petri, M De Rosa - Journal of Medicinal Chemistry, 2024 - ACS Publications
Hepatitis C viral (HCV) infection is the leading cause of liver failure and still represents a
global health burden. Over the past decade, great advancements made HCV curable, and …
global health burden. Over the past decade, great advancements made HCV curable, and …